TrialBritish journal of cancer2023

All HER2-negative breast cancer patients need gBRCA testing: cost-effectiveness and clinical benefits.

Huai-Liang Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.